BioCardia, Inc.
1.3100-0.06 (-4.38%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · BCDA · USD
Key Stats
Market Cap
13.90MP/E (TTM)
-Basic EPS (TTM)
-1.68Dividend Yield
0%Recent Filings
8-K
BioCardia regains Nasdaq compliance
BioCardia, Inc. regained compliance with Nasdaq's Equity Rule 5550(b)(1) on October 2, 2025, after bolstering its balance sheet through fresh capital raises. This ensures continued listing of its common stock on the Nasdaq Capital Market under BCDA. The move supports ongoing development of therapeutic candidates and approved products. Compliance holds amid risks to future fundraising.
8-K
BioCardia regains Nasdaq listing
BioCardia regained Nasdaq compliance on September 24, 2025, after boosting stockholders' equity above the $2.5 million threshold through financings totaling about $7.3 million in net proceeds. These included a $5.1 million registered direct offering of 4.8 million shares and warrants at $1.25 each, plus earlier private placements and ATM sales. Compliance holds for now. Yet Nasdaq will scrutinize future reports for sustained equity levels.
8-K
BioCardia partners on Heart3D imaging
BioCardia inked an exclusive partnership with CART-Tech on August 13, 2025, to develop and commercialize Heart3D Fusion Imaging, fusing 2D X-ray with 3D MRI/CT heart models for precise biotherapeutic delivery and biopsies. BioCardia secures worldwide exclusive distribution for biotherapeutics and U.S. rights for biopsies, starting as a research tool before clinical approval. Management eyes $100 million annual revenue potential from a single approved therapy. Yet risks loom in regulatory hurdles.
10-Q
Q2 FY2025 results
BioCardia posted no revenue in Q2 FY2025 ended June 30, 2025, down from $3K y/y, while operating loss widened to $2.1M from $1.6M y/y and $2.7M q/q (derived), driven by ramped R&D spending on CardiAMP heart failure trial closeout and HF II enrollment start. Net loss hit $2.0M or $(0.40) diluted EPS on 5.1M weighted shares, milder than $(0.88) y/y thanks to a 170% share base expansion from financings, with no material gap between operating and net figures. Cash burned to $981K by quarter-end, with $3.3M operating outflow for H1 less $1 capex yielding negative FCF; equity raises netted $1.9M to offset, but liquidity flags going concern doubts beyond October 2025 absent fresh capital. April and June 2025 closings raised $1.3M via stock and warrants tied to Japanese PMDA approval milestones for CardiAMP. Nasdaq delisting looms if equity compliance isn't regained by September.
8-K
BioCardia Q2 loss widens
BioCardia reported Q2 2025 net loss of $2.0 million, up from $1.6 million last year, driven by $1.4 million in R&D expenses from CardiAMP HF trial closeout and HF II enrollment start. Cash stood at $980,000 on June 30, bolstered by $769,000 ATM proceeds to reach $1.1 million, funding into October. Positive two-year CardiAMP HF data showed lower death and MACCE rates versus control, with FDA and PMDA meetings planned for Q4 2025. Trials advance steadily.
ARMP
Armata Pharmaceuticals, Inc.
5.46+0.47
BCAB
BioAtla, Inc.
0.70-0.04
BRTX
BioRestorative Therapies, Inc.
1.56-0.09
CELU
Celularity Inc.
1.93-0.07
CRDL
Cardiol Therapeutics Inc.
1.14-0.03
CRMD
CorMedix Inc.
11.31+0.17
CYTK
Cytokinetics, Incorporated
61.99+0.02
GDTC
CytoMed Therapeutics Limited
2.18-0.21
MESO
Mesoblast Limited
16.36-0.37
RGBP
Regen Biopharma, Inc.
0.01-0.00